ProCE Banner Activity

CME

Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in CAD

Video

On-demand webcast of expert faculty presentation and case discussion on the modern advances in autoimmune hemolytic anemia and targeting the immune system’s complement system to treat cold agglutinin disease (CAD).

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: December 20, 2023

Expiration: December 19, 2024

No longer available for credit.

Share

Faculty

Catherine M. Broome

Catherine M. Broome, MD

Professor of Medicine
MedStar Georgetown University Hospital
Lombardi Cancer Center
Washington, DC

David Dingli

David Dingli, MD, PhD

Professor of Medicine
Division of Hematology
Mayo Clinic College of Science and Medicine
Rochester, Minnesota

Deva Sharma

Deva Sharma, MD, MS

Assistant Professor of Medicine
Divisions of Transfusion Medicine & Hematology-Oncology
Vanderbilt University Medical Center
Nashville, TN

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Sanofi.

Sanofi

Target Audience

This program is intended for hematologists and other healthcare professionals who care for patients with cold agglutinin disease.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners at integrating new agents into treatment of patients with cold agglutinin disease

Learning Objectives

  • Evaluate the role of complement pathways in the pathophysiology of cold agglutinin disease and associated clinical manifestations in patients with hemolytic anemia

  • Apply current diagnostic criteria for cold agglutinin disease in patients displaying signs and symptoms of autoimmune hemolytic anemia to facilitate an accurate and timely diagnosis

  • Assess the clinical rationale for therapies that inhibit complement-mediated hemolysis in cold agglutinin disease

  • Plan targeted treatment strategies for patients with cold agglutinin disease based on expert recommendations on up-to-date safety and efficacy data and currently approved indications

  • Implement an individualized treatment and supportive care plan for patients with cancer who develop cold agglutinin disease based on patient-specific characteristics

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Catherine M. Broome, MD

Professor of Medicine
MedStar Georgetown University Hospital
Lombardi Cancer Center
Washington, DC

Catherine M. Broome, MD: consultant/advisor/speaker: Alexion, Argenx, Incyte, Sanofi; researcher: Alpine, Rigel, Star Therapeutics.

Primary Author

David Dingli, MD, PhD

Professor of Medicine
Division of Hematology
Mayo Clinic College of Science and Medicine
Rochester, Minnesota

David Dingli, MD, PhD: consultant/advisor/speaker: Alexion, Apellis Pharmaceuticals, AstraZeneca, Janssen, Novartis, Sanofi; data safety monitoring board: Sorrento Therapeutics.

Deva Sharma, MD, MS

Assistant Professor of Medicine
Divisions of Transfusion Medicine & Hematology-Oncology
Vanderbilt University Medical Center
Nashville, TN

Deva Sharma, MD, MS: consultant/advisor/speaker: Novo Nordisk, Sanofi, Terumo Blood and Cell Technologies.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 20, 2023, through December 19, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.